Autotransplants in multiple myeloma: what have we learned?

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• Multiple myeloma (MM) treatment often involves high-dose chemotherapy and stem cell support.
• Tandem transplantation, using two sequential stem cell transplants, is an intensive approach explored for MM.
• Assessing feasibility, outcomes, and prognostic factors of tandem transplants is crucial for MM management.

Purpose of the Study:

• To evaluate the feasibility and efficacy of tandem autotransplants in multiple myeloma patients.
• To identify pre-transplant and post-transplant factors associated with improved event-free survival (EFS) and overall survival (OS).
• To determine the long-term outcomes of patients undergoing tandem transplantation for multiple myeloma.

Main Methods:

• Retrospective analysis of 496 multiple myeloma patients undergoing tandem peripheral blood stem cell transplants.
• Patients received melphalan (MEL 200) for the first transplant; the second transplant varied (MEL 200, MEL 140 with TBI, or alkylating agents).
• Analysis included assessment of treatment-related mortality, complete remission (CR) rates, EFS, OS, and impact of prognostic factors (biomarkers, cytogenetics).

Main Results:

• Tandem transplants were feasible in 73% of patients, with 7% treatment-related mortality in the first year.
• Complete remission (CR) was achieved in 36% of patients, with median EFS of 26 months and median OS of 41 months.
• Low beta 2-microglobulin (B2M) and C-reactive protein (CRP), along with favorable cytogenetics and timely transplant intervals, significantly improved EFS and OS.

Conclusions:

• Tandem transplantation is a feasible approach for a majority of multiple myeloma patients up to age 70.
• Achieving CR and maintaining short intervals between transplants are key to improving survival outcomes.
• Patients with high B2M/CRP and unfavorable cytogenetics represent a high-risk group requiring novel therapeutic strategies.